KR20220126787A - Hiv 및 aids의 치료 및 예방 방법 - Google Patents

Hiv 및 aids의 치료 및 예방 방법 Download PDF

Info

Publication number
KR20220126787A
KR20220126787A KR1020227029968A KR20227029968A KR20220126787A KR 20220126787 A KR20220126787 A KR 20220126787A KR 1020227029968 A KR1020227029968 A KR 1020227029968A KR 20227029968 A KR20227029968 A KR 20227029968A KR 20220126787 A KR20220126787 A KR 20220126787A
Authority
KR
South Korea
Prior art keywords
hiv
administration
once
efda
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227029968A
Other languages
English (en)
Korean (ko)
Inventor
다리아 하주다
마이클 디. 밀러
제이 에이. 그로블러
데보라 앤 니콜-그리피스
Original Assignee
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션 filed Critical 머크 샤프 앤드 돔 코포레이션
Priority to KR1020257028942A priority Critical patent/KR20250136420A/ko
Publication of KR20220126787A publication Critical patent/KR20220126787A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
KR1020227029968A 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법 Ceased KR20220126787A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257028942A KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294,576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297,657 2016-02-19
KR1020217012504A KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
PCT/US2017/017283 WO2017139519A1 (en) 2016-02-12 2017-02-10 Methods for treatment and prophylaxis of hiv and aids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217012504A Division KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257028942A Division KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Publications (1)

Publication Number Publication Date
KR20220126787A true KR20220126787A (ko) 2022-09-16

Family

ID=58057333

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020227029968A Ceased KR20220126787A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020217012504A Ceased KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020257028942A Pending KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020187025948A Active KR102317570B1 (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020217012504A Ceased KR20210049201A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020257028942A Pending KR20250136420A (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법
KR1020187025948A Active KR102317570B1 (ko) 2016-02-12 2017-02-10 Hiv 및 aids의 치료 및 예방 방법

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX2022002925A (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI822652B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN109893536B (zh) * 2018-07-02 2021-04-27 河南真实生物科技有限公司 4’-取代核苷的晶型、制备和应用
EP3823632B1 (en) 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
CA3122576C (en) * 2018-12-20 2025-11-25 Merck Sharp & Dohme Llc CRYSTALLINE FORMS OF THE NRTTI COMPOUND OF 4'-ETHYNYL-2-FLUORO-2'-DESOXYADENOSINE
EP3914604B1 (en) 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权(第2 号)有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
CN102174038A (zh) 2003-02-19 2011-09-07 耶鲁大学 用于治疗病毒感染的抗病毒核苷
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US8513205B2 (en) * 2008-04-11 2013-08-20 Yale University Potent chimeric NRTI-NNRTI bifunctional inhibitors of HIV-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP6934019B2 (ja) * 2016-05-12 2021-09-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ウイルス薬を送達するための薬物送達システム
WO2017222903A1 (en) * 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
JP2020527570A (ja) * 2017-07-18 2020-09-10 ヴィーブ ヘルスケア カンパニー 組み合わせ薬物療法
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
AU2021268584A1 (en) * 2020-05-05 2022-12-01 Merck Sharp & Dohme Llc Drug delivery system for the delivery of antiviral agents and contraceptives
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Also Published As

Publication number Publication date
IL260874A (https=) 2018-09-20
KR20210049201A (ko) 2021-05-04
US20200101098A1 (en) 2020-04-02
JP2021001189A (ja) 2021-01-07
MY197090A (en) 2023-05-24
JP2024001206A (ja) 2024-01-09
IL260874B2 (en) 2023-10-01
UA126375C2 (uk) 2022-09-28
JP6810972B2 (ja) 2021-01-13
AU2017217656A1 (en) 2018-08-23
KR20250136420A (ko) 2025-09-16
TW202417010A (zh) 2024-05-01
CN113509480A (zh) 2021-10-19
RS64448B1 (sr) 2023-09-29
FI3413897T3 (fi) 2023-08-25
EA201891814A1 (ru) 2019-01-31
HK1257347A1 (en) 2019-10-18
PL3413897T3 (pl) 2023-10-02
GEP20207190B (en) 2020-12-10
MX2022002924A (es) 2022-12-15
JP7559175B2 (ja) 2024-10-01
NZ784982A (en) 2025-03-28
AU2020202866B2 (en) 2022-04-07
ZA201805073B (en) 2019-05-29
TW201731514A (zh) 2017-09-16
DOP2018000183A (es) 2018-12-31
WO2017139519A1 (en) 2017-08-17
GEAP202014873A (en) 2020-07-27
HRP20230935T1 (hr) 2023-11-24
AU2022201686A1 (en) 2022-03-31
MX390604B (es) 2025-03-20
PT3413897T (pt) 2023-08-28
CA3013473A1 (en) 2017-08-17
CN108697727A (zh) 2018-10-23
AU2022201686B2 (en) 2024-08-08
US12171776B2 (en) 2024-12-24
JP7021314B2 (ja) 2022-02-16
MD3413897T2 (ro) 2023-11-30
KR102317570B1 (ko) 2021-10-25
TN2018000267A1 (en) 2020-01-16
MX2022002925A (es) 2023-02-10
JOP20170038B1 (ar) 2021-08-17
HUE063532T2 (hu) 2024-01-28
US20180055867A1 (en) 2018-03-01
JP7559175B6 (ja) 2024-10-22
BR112018016349A2 (pt) 2018-12-26
ES2953535T3 (es) 2023-11-14
SG11201806783WA (en) 2018-09-27
SV2018005733A (es) 2018-12-14
GEP20217231B (en) 2021-03-25
NI201800083A (es) 2018-10-05
EP3413897B1 (en) 2023-06-14
NZ745065A (en) 2023-11-24
AU2020202866A1 (en) 2020-05-21
PH12018501712A1 (en) 2019-05-15
JP2022062170A (ja) 2022-04-19
EP3413897A1 (en) 2018-12-19
CA3013473C (en) 2021-10-26
TWI911551B (zh) 2026-01-11
US11337991B2 (en) 2022-05-24
IL260874B1 (en) 2023-06-01
KR20180108815A (ko) 2018-10-04
SI3413897T1 (sl) 2023-11-30
MX2018009763A (es) 2018-11-29
US10537589B2 (en) 2020-01-21
CL2018002150A1 (es) 2018-12-14
US20220331350A1 (en) 2022-10-20
JP2019504857A (ja) 2019-02-21
LT3413897T (lt) 2023-08-25
DK3413897T3 (da) 2023-09-18
AU2017217656B2 (en) 2020-01-30
US20250073254A1 (en) 2025-03-06
TWI822652B (zh) 2023-11-21

Similar Documents

Publication Publication Date Title
KR102317570B1 (ko) Hiv 및 aids의 치료 및 예방 방법
HK40054462A (en) Methods for treatment and prophylaxis of hiv and aids
AU2018239257A1 (en) HIV post-exposure prophylaxis
HK1257347B (en) Methods for treatment and prophylaxis of hiv and aids
TW202610660A (zh) 治療及預防hiv與aids之方法
EA042565B1 (ru) СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа
US20220265689A1 (en) Hiv pre-exposure prophylaxis

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104